Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Pharma
Biokin, BMS' bispecific ADC hits goal in China lung cancer trial
With the positive readout in EGFR-mutated NSCLC, iza-bren poses another threat to TROP2-targeted ADCs.
Angus Liu
Aug 18, 2026 11:18am
AstraZeneca dual lung cancer wins softened by bispecific fail
Aug 17, 2026 10:56am
Summit updates ivonescimab survival data ahead of PDUFA
Jul 22, 2026 10:58am
AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B
Jul 14, 2026 9:57am
Dizal takes on J&J with first-line win in EGFR lung cancer type
May 29, 2026 8:00am
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
Mar 23, 2026 10:25am
